■目前皮肤T细胞淋巴瘤(CTCL)的治疗指南提倡阶段驱动的方法,考虑到临床表现,症状负担,和病人合并症。治疗选择取决于疾病亚型等因素,严重程度,和治疗的可用性。主要目标是通过减轻症状来提高生活质量,因为实现持久的完全缓解是罕见的。
■过去十年(2013-2023年),随着创新疗法的引入,CTCL的治疗前景经历了重大转变。这篇综述探讨了传统治疗方案和最近推出的药物的主要关键发展。旨在为临床医生和研究人员提供关于该领域十年进展的全面视角。
■尽管在CTCL治疗方面取得了进展,从局部化疗药物到免疫调节剂,一些未满足的需求仍然存在。首先,迫切需要纳入治疗反应的现成预测因子,包括临床,病态,和分子特征。其次,对肿瘤微环境的更深刻的理解对于优化可靶向分子的景观是必要的。最后,应鼓励开展联合治疗方案的研究,因为它通过协同组合具有多种作用方式的药物来提高治疗效果。
UNASSIGNED: Current treatment guidelines for cutaneous T cell lymphoma (CTCL) advocate a stage-driven approach, considering clinical presentation, symptom burden, and patient comorbidities. Therapy selection hinges on factors like disease subtype, severity, and treatment availability. The primary goal is to enhance the quality of life by mitigating symptoms, as achieving lasting complete remission is infrequent.
UNASSIGNED: Over the past decade (2013-2023), the therapeutic landscape of CTCL has experienced substantial transformation with the introduction of innovative therapies. This review explores the main pivotal developments in traditional treatment schedules and recently introduced drugs, aiming to offer clinicians and researchers a thorough perspective on the decade\'s progress in the field.
UNASSIGNED: Despite the progress made in CTCL therapeutics, ranging from topical chemotherapeutics to immunomodulatory agents, several unmet needs persist. Firstly, there is a pressing need for the incorporation of readily available predictors for treatment response, encompassing clinical, pathological, and molecular features. Secondly, a more profound comprehension of the tumor microenvironment is imperative to optimize the landscape of targetable molecules. Lastly, the undertaking of studies on combination regimens should be encouraged as it enhances therapy efficacies by synergistically combining agents with diverse modes of action.